These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 28795288)

  • 1. Novel Agents in the Treatment of Thymic Malignancies.
    Merveilleux du Vignaux C; Maury JM; Girard N
    Curr Treat Options Oncol; 2017 Aug; 18(9):52. PubMed ID: 28795288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic treatment for thymic malignancies.
    Girard N; Merveilleux du Vignaux C
    Curr Opin Oncol; 2017 Mar; 29(2):112-117. PubMed ID: 28027106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Drug Targets for Thymic Neoplasms.
    Xu XL; Mao WM
    Curr Cancer Drug Targets; 2015; 15(7):593-603. PubMed ID: 26077729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors.
    Serpico D; Trama A; Haspinger ER; Agustoni F; Botta L; Berardi R; Palmieri G; Zucali P; Gallucci R; Broggini M; Gatta G; Pastorino U; Pelosi G; de Braud F; Garassino MC
    Ann Oncol; 2015 May; 26(5):838-847. PubMed ID: 25411417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy and targeted agents for thymic malignancies.
    Girard N
    Expert Rev Anticancer Ther; 2012 May; 12(5):685-95. PubMed ID: 22594902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymic malignancies: emerging systemic therapies.
    Girard N
    Curr Opin Oncol; 2019 Sep; 31(5):454-460. PubMed ID: 31394557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy.
    Katsuya Y; Horinouchi H; Asao T; Kitahara S; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Watanabe S; Tsuta K; Ohe Y
    Lung Cancer; 2016 Sep; 99():4-10. PubMed ID: 27565906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemotherapy for thymic carcinoma].
    Okuma Y
    Gan To Kagaku Ryoho; 2012 May; 39(5):702-7. PubMed ID: 22584319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymic epithelial tumours: from basic principles to individualised treatment strategies.
    Girard N
    Eur Respir Rev; 2013 Mar; 22(127):75-87. PubMed ID: 23457169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do thymic malignancies respond to target therapies?
    Hu B; Rong H; Han Y; Li Q
    Interact Cardiovasc Thorac Surg; 2015 Jun; 20(6):855-9. PubMed ID: 25754373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic therapeutic options in thymic malignancies: a glimmer of hope.
    Hammond-Thelin LA; Thomas CR
    Rev Recent Clin Trials; 2007 Sep; 2(3):191-205. PubMed ID: 18474005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymic malignancies: next-generation sequencing as a tool to select patients for targeted therapies and immunotherapies?
    Girard N
    Mediastinum; 2019; 3():38. PubMed ID: 35118264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precise Diagnosis and Treatment of Thymic Epithelial Tumors Based on Molecular Biomarkers.
    Du J; Zhou XJ
    Crit Rev Oncog; 2017; 22(5-6):507-514. PubMed ID: 29604928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic options in thymomas and thymic carcinomas.
    Muto Y; Okuma Y
    Expert Rev Anticancer Ther; 2022 Apr; 22(4):401-413. PubMed ID: 35266421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports.
    Simonelli M; Zucali PA; Suter MB; Lorenzi E; Rubino L; Fatuzzo G; Alloisio M; Santoro A
    Future Oncol; 2015; 11(8):1223-32. PubMed ID: 25832879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
    Maxwell R; Jackson CM; Lim M
    Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy.
    Kossai M; Duchemann B; Boutros C; Caramella C; Hollebecque A; Angevin E; Gazzah A; Bahleda R; Ileana E; Massard C; Vielh P; Soria JC; Besse B
    Lung Cancer; 2015 Sep; 89(3):306-10. PubMed ID: 26160757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic treatment of advanced thymic malignancies.
    Kelly RJ
    Am Soc Clin Oncol Educ Book; 2014; ():e367-73. PubMed ID: 24857125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymic malignancies: from clinical management to targeted therapies.
    Kelly RJ; Petrini I; Rajan A; Wang Y; Giaccone G
    J Clin Oncol; 2011 Dec; 29(36):4820-7. PubMed ID: 22105817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Overview of the Use of Anti-Angiogenic Agents in the Treatment of Thymic Epithelial Tumors.
    Agrafiotis AC; Berzenji L; Koyen S; Vermeulen D; Winthagen R; Hendriks JMH; Van Schil PE
    Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.